Health Care [ 10/12 ] | Biotechnology [ 44/73 ]
NYSE | Common Stock
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States.
The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3 to treat parkinson's disease; and is in phase 2 clinical trial to treat lewy body dementia.
It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial to treat later stages of alzheimer's disease and dementia.
The company was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 12, 25 | -0.32 Increased by 0.00% | -0.40 Increased by +20.62% |
| May 8, 25 | -0.32 Increased by +55.56% | -0.80 Increased by +60.00% |
| Mar 27, 25 | -0.43 Increased by +80.80% | -0.20 Decreased by -115.00% |
| Nov 6, 24 | -0.97 Increased by +40.49% | -0.53 Decreased by -83.02% |
| Aug 14, 24 | -0.32 Increased by +70.09% | -0.63 Increased by +49.21% |
| May 10, 24 | -0.72 Increased by +39.50% | -0.80 Increased by +10.00% |
| Mar 29, 24 | -2.24 Decreased by -113.33% | -1.30 Decreased by -72.31% |
| Nov 8, 23 | -1.63 Decreased by -75.27% | -1.09 Decreased by -49.54% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 0.00 Decreased by N/A% | -6.22 M Decreased by -23.91% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -5.54 M Decreased by -418.93% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by N/A% | -5.87 M Increased by +73.60% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -12.64 M Increased by +14.12% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -5.02 M Increased by +47.36% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -1.07 M Increased by +96.38% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -22.21 M Decreased by -635.38% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -14.72 M Decreased by -95.81% | Decreased by N/A% Decreased by N/A% |